- Home
- PRQR vs ZNTL Comparison
PRQR vs ZNTL Comparison
Compare PRQR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | ZNTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.1M | 289.0M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRQR | ZNTL |
|---|---|---|
| Price | $1.69 | $4.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $7.25 | $6.60 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $1.21 |
| 52 Week High | $3.10 | $6.95 |
Technical Indicators
Market Signals| Indicator | PRQR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 54.68 |
| Support Level | $1.40 | $3.53 |
| Resistance Level | $1.70 | $5.11 |
| Average True Range (ATR) | 0.15 | 0.44 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.86 | 62.02 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.